LENZ Therapeutics, Inc.
LENZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $15 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | -$0 | $0 | $15 | -$1 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $30 | $60 | $21 | $38 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $29 | $13 | $4 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $59 | $72 | $25 | $60 |
| Operating Income | -$59 | -$72 | -$10 | -$60 |
| % Margin | – | – | -69.9% | – |
| Other Income/Exp. Net | $9 | $2 | $0 | -$10 |
| Pre-Tax Income | -$50 | -$70 | -$10 | -$71 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$50 | -$70 | -$11 | -$71 |
| % Margin | – | – | -72.1% | – |
| EPS | -2.34 | -15.3 | -12.891 | -8.538 |
| % Growth | 84.7% | -18.7% | -51% | – |
| EPS Diluted | -2.34 | -15.3 | -12.891 | -8.538 |
| Weighted Avg Shares Out | 21 | 8 | 8 | 8 |
| Weighted Avg Shares Out Dil | 21 | 8 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $2 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$50 | -$72 | -$10 | -$70 |
| % Margin | – | – | -69.8% | – |